Skip to main content

AsclepiX Therapeutics, Inc., Raises $35M for Blindness-Fighting Therapies

AsclepiX Therapeutics, Inc. , a Baltimore City-based biopharmaceutical company out of The Johns Hopkins University, has raised $35M in new Series A funding to support development of blindness-fighting therapies. According to the Baltimore Business Journal, the new financing will be used to fund clinical trials of AsclepiX's lead therapy candidate which will launch this year. The company has three additional therapies in its development pipeline targeting ocular diseases and cancer. #regiononpoint #healthcare #lifesciences #investment #biopharma #blindness #cancer

Read More

Subscribe to our mailing list: